Institute of Hematology & Blood Diseases Hospital, China clinical trials
Listed in the registry as: University, hospital or other organization.
The registry lists 402 studies whose lead sponsor is Institute of Hematology & Blood Diseases Hospital, China. 296 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 21, 2026.
Keep track of what changes. Save the Institute of Hematology & Blood Diseases Hospital, China studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesStatus
Focus areas
Conditions Institute of Hematology & Blood Diseases Hospital, China leads ten or more studies in, by study count. A broader condition is left out when almost all its studies are already in a narrower one listed here.
Studies
Recruiting first, then most recently updated. Showing 50 of 402. Browse all 402 →
- daGOAT-Guided Prevention of Severe aGVHD After Allo-HSCTNot yet recruitingNCT07588945Phase 3
- Using Mobile Technology-assisted Outpatient Maintenance Therapy Pediatric ALLRecruitingNCT07278882Not applicable
- Nutritional Intervention for Patients Undergoing Allogeneic Hematopoietic Stem Cell TransplantationNot yet recruitingNCT07850375Not applicable
- BCMA/CD3 BsAb Therapy for POEMS SyndromeRecruitingNCT07115654Phase 2
- Immunotargeted Therapy Plus Low-Dose Chemotherapy in Newly Diagnosed Adult Ph+ B-ALLNot yet recruitingNCT07840976Phase 2
- Human Albumin Combined With Plasma Exchange for Frailty InterventionNot yet recruitingNCT07836127Not applicable
- META 10-19 in Patients With Relapsed/Refractory Autoimmune Hemolytic AnemiaNot yet recruitingNCT07689604Early Phase 1
- A Clinical Study on the Efficacy and Safety of Zeprumetostat in Relapsed/Refractory Large Granular Lymphocyte LeukemiaNot yet recruitingNCT07692529Phase 1
- Phase I/II Study of Anti-CD38 Monoclonal Antibody in Refractory Severe Aplastic AnemiaRecruitingNCT07714512Phase 1/2
- Rituximab, Pirtobrutinib, Lisaftoclax and Liposomal Mitoxantrone for for Richter Syndrome Transformed From CLLNot yet recruitingNCT07831395Phase 2
- CM336 Plus Daratumumab and Lenalidomide in Transplant-Ineligible Newly Diagnosed Multiple MyelomaNot yet recruitingNCT07830485Phase 2
- Brain Cognitive Network Abnormalities in Anemia Patients Using fNIRSRecruitingNCT07578675
- CM336 Plus Isa-VR in Newly Diagnosed Primary Plasma Cell LeukemiaRecruitingNCT07652905Phase 2
- Liposomal Mitoxantrone Plus Azacitidine and Venetoclax in Newly Diagnosed Elderly or Unfit AMLNot yet recruitingNCT07828535Phase 1
- F182112 in Combination With Isatuximab and Lenalidomide for the Treatment of Patients With Newly Diagnosed Multiple MyelomaNot yet recruitingNCT07828522Phase 2
- CM336 Plus Isatuximab for Newly Diagnosed Multiple Myeloma With Renal ImpairmentRecruitingNCT07585760Phase 2
- Phase 1 Study of F182112 in Relapsed/Refractory Autoimmune Hemolytic AnemiaNot yet recruitingNCT07816341Phase 1
- HP-001 Plus Dexamethasone for Relapsed/Refractory Multiple Myeloma With Extramedullary DiseaseNot yet recruitingNCT07811986Phase 2
- A Study of Bometase Alfa for Bleeding Control in Acquired Hemophilia ANot yet recruitingNCT07789587Not applicable
- Safety and Efficacy of Elranatamab Plus Isatuximab, Bortezomib, and Lenalidomide in Ultra-High-Risk Multiple MyelomaNot yet recruitingNCT07789522Phase 2
- Study for Safety and Efficacy of Olverembatinib Combined With APG-2575 in Children With Relapsed/Refractory Ph + ALLRecruitingNCT05495035Phase 1
- CM336-SOC for Dynamically High-Risk Multiple Myeloma StudyNot yet recruitingNCT07648459Phase 2
- A Randomized Trial of Venetoclax-Based Induction Intensity in Newly Diagnosed Acute Myeloid LeukemiaNot yet recruitingNCT07754799Phase 2
- Multi-target Drugs Sequential Combination Therapy in Adults Patients With Newly Diagnosed Primary Immune ThrombocytopeniaRecruitingNCT07788456Phase 4
- A Study of Elranatamab for Inhibitor Eradication in Patients With Hemophilia ANot yet recruitingNCT07788469Not applicable
- A Clinical Study of HY035 Cell Injection in the Treatment of CD7-positive Relapsed or Refractory Hematologic MalignanciesEnrolling by invitationNCT07784309Phase 1
- Autologous Hematopoietic Stem Cell Transplantation for Neurological Damage Associated With Hereditary Homocysteine Remethylation DisordersNot yet recruitingNCT07757685Not applicable
- Salvage Chemotherapy With Sonrotoclax, Cladribine, and Standard-dose Cytarabine, Sequentially Followed by HSCT for R/R AML.Not yet recruitingNCT07757672Phase 1/2
- Intermediate-dose HAD Regimen for CEBPA Double-mutated AMLRecruitingNCT06529250Not applicable
- MRD-positive AML Clinical StudyRecruitingNCT07131059Not applicable
- Metformin Inhibits DNMT3A Clonal Hematopoiesis in Acute LeukemiaRecruitingNCT07188740Phase 1
- Pediatric-Inspired Regimen Combined With Venetoclax and Immunotherapy for Adult Ph-Negative Acute Lymphoblastic LeukemiaRecruitingNCT07495631Not applicable
- ASCT in Combination With C-CAR088 for Treating Patients With Ultra High-risk Multiple Myeloma (MM)RecruitingNCT05632380Phase 1/2
- Standard-dose vs Intermediate-dose Cytarabine Induction in the Treatment of Acute Myeloid Leukemia With RUNX1-RUNX1T1RecruitingNCT06744504Phase 3
- Multicenter, Platform-type Clinical Study of Refractory/Recurrent Acute Myeloid LeukemiaRecruitingNCT06265545Not applicable
- MRD-Guided BCMA/CD3 Bispecific Antibody Treatment After Stem Cell Transplant for Newly Diagnosed Multiple MyelomaRecruitingNCT07409454Phase 2
- Venetoclax, Azacitidine and Liposomal Mitoxantrone for Newly Diagnosed AMLRecruitingNCT07490288Not applicable
- BCMA/GPRC5D Trispecific Antibody Treatment for Newly Diagnosed Amyloidosis (AL-004)Not yet recruitingNCT07751471Phase 2
- Plasma ctDNA Monitoring in Pediatric Acute LeukemiaNot yet recruitingNCT07751588
- A Study of KIV-318 Injection in Patients With BCMA-Positive Relapsed/Refractory Multiple MyelomaNot yet recruitingNCT07726160Phase 1
- SHR2554 Plus Liposomal Mitoxantrone as First-line Treatment for Peripheral T-cell Lymphoma (PTCL)Not yet recruitingNCT07725705Phase 1/2
- Newly-diagnosed Intermediate/High Risk Pediatric B-cell ALL ProtocolRecruitingNCT06764238Phase 2/3
- Chemotherapy With Targeted-Immunotherapy for Newly Diagnosed Ph+ ALLRecruitingNCT07493161Not applicable
- BCMA/CD3 BsAb in the Treatment of High-risk Smoldering Multiple MyelomaRecruitingNCT06745687Not applicable
- BCMA/CD3 Bispecific Antibody Treatment for Newly Diagnosed AmyloidosisRecruitingNCT07151690Phase 2
- A Study of Injectable BLB101 and Blincyto® in Adult Participants With R/R CD19+ B-ALLNot yet recruitingNCT07723911Phase 3
- Eltrombopag Plus Telitacicept vs. Eltrombopag Alone for Steroid-refractory/Relapsed ITPNot yet recruitingNCT07687134Phase 2
- Lisaftoclax Plus Azacitidine Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia Patients at High Risk of RelapseNot yet recruitingNCT07686965Phase 3
- Sonrotoclax and BCMA Bispecific Antibody in Newly Diagnosed Systemic AL Amyloidosis Based on t(11;14) Genetic StratificationNot yet recruitingNCT07687004Phase 1/2
- rhTPO Dose Escalation vs Eltrombopag Switch in ITPNot yet recruitingNCT07476846Not applicable